About AvaChrome
Humanized Mice
Disruptive Technology
Disruptive Technology
AvaChrome provides human physiological models of liver-based chimeric mice (huminazed mice) for significantly improved drug metabolism and safety testing.
Disruptive Technology
Disruptive Technology
Disruptive Technology
AvaChrome develops its proprietary disruptive technology to dramatically improve drug metabolism and toxicology evaluation of early to late stage preclinical drug candidates.
New Gold Standard
Disruptive Technology
New Gold Standard
AvaChrome believes that improved humanized platforms will become the new gold standard and thus an essential element of drug development.
Our Team
Emmanuel E. "Ed" Baetge
Karl-Dimitter "Dimi" Bissig
Karl-Dimitter "Dimi" Bissig
PhD
Chairman & CEO AvaChrome
Ed has 30+ years of experience in biotechnology ranging from traditional pharmaceutical companies to university spin-offs. He has successfully created, developed and managed biotechs companies and research institutes. Dr. Baetge is currently a Venture Partner at NanoDimension.
Karl-Dimitter "Dimi" Bissig
Karl-Dimitter "Dimi" Bissig
Karl-Dimitter "Dimi" Bissig
MD - PhD
President & CSO AvaChrome
Dimi has a 15+ years of experience and is an academic leader in the field of human liver chimeric mice. He is a serial pioneer in this field and has a fundamental understanding of the opportunities and challenges of huminazed mice. Dr. Bissig is currently Associate Professor at Duke University, School of Medicine.
Mercedes Barzi Dieguez
Karl-Dimitter "Dimi" Bissig
Mercedes Barzi Dieguez
PhD
Research Director
Mercedes has a 10+ years of experience and is an expert in huminazed mice. She has been part of the developement team of the PIRF mouse and masters all challenges in strain development. Dr. Barzi is currently Medical Instructor at Duke University, School of Medicine.
